Tuesday, 15 June, 2021

Good News on Oxford’s COVID-19 Vaccine

Oxford and Astra Zeneca vaccine achieved 99 percent immunity in phase 2 Oxford COVID Vaccine Safe, Effective, Especially in Older Adults
Gustavo Carr | 22 November, 2020, 15:54

Days after US-based biotechnology Moderna's vaccine showed 94.5 per cent efficacy in fight against COVID-19 infection, the Company's Chief Executive said that they will charge governments between $25 and $37 per dose of its COVID-19 vaccine candidate, depending on the amount ordered.

"It is essential that a COVID-19 vaccine can be effective across a broad age range, particularly in older individuals where they are disproportionately at risk of severe COVID-19 disease".

American company Pfizer and German firm BioNTech announced on November 9 that their candidate, called BNT162b2, was more than 90 percent effective in preventing COVID-19.

The phase 2 trial of the ChAdOx1 nCoV-19 vaccine included 560 healthy adults, including 240 older than 70.

Phase 3 testing for the AstraZeneca and Oxford vaccine is underway around the world.

This is a great development because among the many developers that released the results of their Stage 3 human clinical trial, only Oxford revealed the demographics of its participants. "People have had only mild symptoms", Liu Jingzhen, chairmen of Sinopharm, said in an interview, as reported by South China Morning Post.

See Images Of The Impressive "Strawberry Moon" In Greece
If only the name implied we'd see something as exciting as a literal strawberry shape forming across the moon. During a partial eclipse, some part of the Moon is blocked by the Earth while remaining is visible.

The Serum Institute of India, the world's largest vaccine manufacturer, has already manufactured millions of doses of the vaccine that is being developed in collaboration with Oxford University while results from late-stage trials are awaited.

"In terms of emergency use, the vaccines were applied to almost a million people and there has not been a single case of a serious adverse event". He told the British Broadcasting Corporation (BBC) on Thursday that he was "delighted" that early results show a strong immune response "even in those over 70 years of age".

The researchers from The University of Oxford and AstraZeneca began working on the vaccine in January and they started their human clinical trials in April.

Pollard reportedly added that there wasn't "any competition" against other vaccines.

However, experts have warned against the vaccine due to a lack of standard control from any clinical trial group.

While waiting for the full result of Stage 3 human clinical trial, the United Kingdom government has already ordered 100 million doses.